Eurofins BioPharma Product Testing delivers vital COVID-19 testing for all drug modalities and supply chains
Press Release - Monday, April 20, 2020
Eurofins BioPharma Product Testing partners with the world’s most innovative Bio/Pharmaceutical firms to advance timely therapies to patients in need. As the world strives to combat the COVID-19 pandemic, BioPharmaceutical, Government, and non-profit organizations are working diligently to identify new or existing drug modalities that potentially can be used to treat COVID-19 affected populations. Eurofins BioPharma Product Testing’s scientific expertise and breadth of testing capabilities places the company at the forefront in supporting clients’ mission to accelerate COVID-19 drug and vaccine development and put an end to this crisis.
With the race to deliver life-saving therapies and safe medical devices to patients and medical staff, Eurofins BioPharma Product Testing is providing clients with trusted and expedited COVID-19 testing support for all modalities and parts of the supply chain, including Antivirals, Vaccines, mAbs, Antibodies, RNA, and Testing Kits, with expertise in:
- Raw Materials Testing
- Product Testing
- Viral Testing
- Microbiology
- Cell Banking
- Cell and Molecular Testing
- Stability and Release Testing and Method Development
- Medical Device Testing and Method Development
Backed by decades of scientific experience, vast range of capabilities, and driven work ethic, Eurofins BioPharma Product Testing stands together with clients in working non-stop to provide COVID-19 testing support wherever needed as we all strive to make the world healthier and safer. For more information on Eurofins BioPharma Product Testing’s comprehensive testing services portfolio, please visit: www.Eurofins.com/BPT. Discover Eurofins Scientific’s global COVID-19 testing support initiatives: https://www.eurofins.com/covid-19-response/
For Further Information
Eurofins BioPharma Product Testing
Eurofins BioPharma Product Testing—the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide—offers complete CMC Testing Services for the Bio/Pharmaceutical industry, including all starting materials, process intermediates, drug substances, drug product, packaging, and manufacturing support through our broad technical expertise in Biochemistry, Molecular & Cell Biology, Virology, Chemistry and Microbiology. With a global capacity of more than 150,000 square meters and 35 facilities located in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, India, Japan, Netherlands, New Zealand, Spain, Sweden, Switzerland, UK and the US, Eurofins BioPharma Product Testing’s network of GMP laboratories and vast experience allow it to support projects of any size from conception to market. Further, the company has teams of scientists placed at more than 70 client facilities worldwide through award-winning Professional Scientific Services® (PSS) insourcing program.
Eurofins – a global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).For more information, please visit www.eurofins.com.